Citadel Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$135K Sell
113,700
-124,100
-52% -$217K ﹤0.01% 11777
2025
Q4
$480K Buy
237,800
+175,200
+280% +$377K ﹤0.01% 9125
2025
Q3
$125K Buy
62,600
+47,600
+317% +$83.7K ﹤0.01% 11674
2025
Q2
$29.1K Sell
15,000
-23,200
-61% -$30.9K ﹤0.01% 11994
2025
Q1
$30.6K Buy
38,200
+16,400
+75% +$32.6K ﹤0.01% 12802
2024
Q4
$51.4K Buy
+21,800
New +$37.4K ﹤0.01% 12365
2024
Q2
Sell
-3,500
Closed -$6.26K 14982
2024
Q1
$6.26K Sell
3,500
-300
-8% -$487 ﹤0.01% 13690
2023
Q4
$6.35K Hold
3,800
﹤0.01% 13359
2023
Q3
$11.8K Sell
3,800
-2,300
-38% -$7.15K ﹤0.01% 12992
2023
Q2
$17.4K Sell
6,100
-71,400
-92% -$269K ﹤0.01% 12851
2023
Q1
$305K Buy
77,500
+69,200
+834% +$253K ﹤0.01% 9350
2022
Q4
$32.9K Sell
8,300
-110,500
-93% -$582K ﹤0.01% 12627
2022
Q3
$1.09M Buy
118,800
+82,800
+230% +$628K ﹤0.01% 6809
2022
Q2
$214K Buy
+36,000
New +$221K ﹤0.01% 10557
2021
Q3
Sell
-40,300
Closed -$222K 14331
2021
Q2
$222K Buy
40,300
+15,900
+65% +$90.2K ﹤0.01% 11933
2021
Q1
$141K Buy
+24,400
New +$179K ﹤0.01% 12123

Other funds holding MIST

Citadel Advisors's MIST Position: Q1 2026 in Review

Citadel Advisors reduced its Milestone Pharmaceuticals (MIST) stake by 44% in Q1 2026, selling an estimated $274K and leaving 196,696 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #11067.

Citadel Advisors first reported a position in MIST in Q3 2021 and has held it in 14 quarters since. The position peaked at $5.49M in Q3 2022. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Citadel Advisors held 196,696 shares of Milestone Pharmaceuticals worth $234K as of Q1 2026.
  • Citadel Advisors sold 156,536 Milestone Pharmaceuticals shares in Q1 2026, an estimated $274K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11067 holding.
  • Citadel Advisors first reported a position in Milestone Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Milestone Pharmaceuticals position peaked at $5.49M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.